GLP-1 Drugs and Hidradenitis Suppurativa: Early Studies, No Trial

Hidradenitis suppurativa and obesity often go together, and losing weight has been associated with improvement in symptoms. So the question of whether a GLP‑1 helps is a reasonable one, and early studies of liraglutide and semaglutide have reported improvement in disease severity and quality of life.^[1] There is no randomized trial. The best available summary is a review whose own title ends in a question mark, and that is where the evidence stands.

What is established, and what is not

HS is an inflammatory skin disorder producing painful, draining nodules in skin folds, which can progress to sinus tracts. Obesity is more common in people with HS than in the general population, and may predispose to it. Weight loss has been associated with symptom improvement. All of that is settled enough to build on.^[1]

What is not settled is whether adding a GLP‑1 changes the disease. The review describes early studies of liraglutide and semaglutide showing improvement in severity and quality of life, and proposes two mechanisms: reduced mechanical stress on affected skin, and moderation of inflammation. “Early studies” and “proposed mechanism” are the operative phrases.^[1]

How to read an early result in a painful condition

HS is severe enough that people reasonably want to try things. That is the situation in which early, unblinded, uncontrolled results are most persuasive and least reliable: a condition that flares and remits on its own, an outcome partly scored by how a patient feels, and a treatment everyone involved is hoping will work.

The finding may still be right. But it is the kind that requires a controlled trial before anybody should count on it, and the absence of such a trial is the single most important thing to know before deciding.

• No GLP-1 is approved for hidradenitis suppurativa. Any use for it would be off-label.
• The evidence is early-stage studies summarized in a narrative review, not a randomized trial.
• Established HS treatments, including biologics with randomized evidence, are not displaced by any of this.
• If you carry excess weight and have HS, weight loss deserves discussion on its own merits, with the caveat that its effect on HS specifically has been mixed.
• Decisions here belong with a dermatologist who knows your disease stage. An article summarizing a review cannot substitute for that.

For a skin condition where a randomized trial of a GLP‑1 alongside a biologic does exist, see a biologic plus tirzepatide for psoriasis.